Inclusion Criteria : 
   1.  Female , age ≥  18 years and ≤  70 years , signed informed consent . 
   2.  Histologically or pathologically confirmed diagnosis of epithelial carcinoma of the ovary . 
   3.  Platinum resistant ovarian cancer ( defined as relapsing within  6 months after the last administration of platinum - based chemotherapy ) OR platinum refractory ovarian cancer ( defined as progressing while on a platinum - based chemotherapy ) 
   4.  At least treated with one line of platinum - based chemotherapy
   5.  Eastern Cooperative Oncology Group ( ECOG ) performance status  0 -  2 
   6.  Measurable disease according to Response Evaluation Criteria in Solid Tumors ( RECIST )  1.1 version or CA 125     
   7.  Patients must have a life expectancy of at least  3 months . 
   8.  Patients must have adequate organ function . 
Exclusion Criteria : 
   1.  Had prior exposure to anlotinib or has known allegies to any of the excipients , Inadequately controlled hypertension
   2.  History of myocardial infarction , or unstable angina , or New York Heart Association ( NYHA ) Grade III - IV within  6 months prior to Day  1. 
   3.  History of abdominal fistula or gastrointestinal perforation within  28 days prior to Day  1 
   4.  Major surgical procedure within  28 days prior to Day  1 , Serious , non - healing wound , active ulcer , bowel obstruction within  28 days prior to Day  1 
   5.  Symptomatic central nervous system ( CNS ) metastasis
